Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab-methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study.
Bromberg JEC, Issa S, van der Holt B, van der Meulen M, Dirven L, Minnema MC, Seute T, Durian M, Cull G, van der Poel MWM, Stevens WBC, Zijlstra JM, Brandsma D, Nijland M, Mason KD, Beeker A, Abrahamse-Testroote MCJ, van den Bent MJ, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: beeker a. Neuro Oncol. 2024 Apr 5;26(4):724-734. doi: 10.1093/neuonc/noad224. Neuro Oncol. 2024. PMID: 38037691 Free PMC article. Clinical Trial.
Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.
van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerdt O, Kater AP. van Gelder M, et al. Among authors: beeker a. Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15. Bone Marrow Transplant. 2016. PMID: 26878656 Clinical Trial.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, Cull G, Schouten HC, Stevens WBC, Zijlstra JM, Baars JW, Nijland M, Mason KD, Beeker A, van den Bent MJ, Beijert M, Gonzales M, de Jong D, Doorduijn JK. Bromberg JEC, et al. Among authors: beeker a. Lancet Oncol. 2019 Feb;20(2):216-228. doi: 10.1016/S1470-2045(18)30747-2. Epub 2019 Jan 7. Lancet Oncol. 2019. PMID: 30630772 Clinical Trial.
Rituximab-PECC induction followed by 90 Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study.
Lugtenburg PJ, Zijlstra JM, Doorduijn JK, Böhmer LH, Hoogendoorn M, Berenschot HW, Beeker A, van der Burg-de Graauw NC, Schouten HC, Bilgin YM, Kersten MJ, Koene HR, Herbers AHE, de Jong D, Hijmering N, Lam KH, Chiţu D, Brouwer RE, van Imhoff GW; Dutch HOVON group. Lugtenburg PJ, et al. Among authors: beeker a. Br J Haematol. 2019 Nov;187(3):347-355. doi: 10.1111/bjh.16087. Epub 2019 Jul 10. Br J Haematol. 2019. PMID: 31290569 Free article. Clinical Trial.
HOVON110/ReBeL Study: Results of the Phase I Part of a Randomized Phase I/II Study of Lenalidomide, Rituximab With or Without Bendamustine in Patients With Relapsed/Refractory Follicular Lymphoma.
Stevens WBC, Bakunina K, Cuijpers M, Chamuleau M, Beeker A, Fijnheer R, Hebart H, Visser HPJ, Doorduijn JK, Linton K, Dreyling M, de Jong D, Kersten MJ. Stevens WBC, et al. Among authors: beeker a. Hemasphere. 2020 Jan 3;4(1):e325. doi: 10.1097/HS9.0000000000000325. eCollection 2020 Feb. Hemasphere. 2020. PMID: 32072141 Free PMC article.
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study.
van der Meulen M, Bakunina K, Nijland M, Minnema MC, Cull G, Stevens WBC, Baars JW, Mason KD, Beeker A, Beijert M, Taphoorn MJB, van den Bent MJ, Issa S, Doorduijn JK, Bromberg JEC, Dirven L. van der Meulen M, et al. Among authors: beeker a. Ann Oncol. 2020 Aug;31(8):1046-1055. doi: 10.1016/j.annonc.2020.04.014. Epub 2020 May 3. Ann Oncol. 2020. PMID: 32371123 Free article. Clinical Trial.
Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84).
Lugtenburg PJ, de Nully Brown P, van der Holt B, D'Amore FA, Koene HR, de Jongh E, Fijnheer R, van Esser JW, Böhmer LH, Pruijt JF, Verhoef GE, Hoogendoorn M, Bilgin MY, Nijland M, van der Burg-de Graauw NC, Oosterveld M, Jie KG, Larsen TS, van der Poel MW, Leijs MB, Silbermann MH, van Marwijk Kooy M, Beeker A, Kersten MJ, Doorduijn JK, Tick LW, Brouwer RE, Lam KH, Burggraaff CN, de Keizer B, Arens AI, de Jong D, Hoekstra OS, Zijlstra-Baalbergen JM. Lugtenburg PJ, et al. Among authors: beeker a. J Clin Oncol. 2020 Oct 10;38(29):3377-3387. doi: 10.1200/JCO.19.03418. Epub 2020 Jul 30. J Clin Oncol. 2020. PMID: 32730183 Clinical Trial.
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: beeker a. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article. Clinical Trial.
Extent of radiological response does not reflect survival in primary central nervous system lymphoma.
van der Meulen M, Postma AA, Smits M, Bakunina K, Minnema MC, Seute T, Cull G, Enting RH, van der Poel M, Stevens WBC, Brandsma D, Beeker A, Doorduijn JK, Issa S, van den Bent MJ, Bromberg JEC. van der Meulen M, et al. Among authors: beeker a. Neurooncol Adv. 2021 Feb 15;3(1):vdab007. doi: 10.1093/noajnl/vdab007. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 33615224 Free PMC article.
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma.
Al-Sarayfi D, Meeuwes FO, Durmaz M, Issa DE, Brouwer RE, Beeker A, van Rhenen A, Mutsaers PGNJ, Böhmer LH, van der Poel MWM, Te Boome L, van Meerten T, Chamuleau MED, Zijlstra JM, Brink M, Nijland M. Al-Sarayfi D, et al. Among authors: beeker a. Blood Cancer J. 2022 Sep 2;12(9):125. doi: 10.1038/s41408-022-00723-4. Blood Cancer J. 2022. PMID: 36055987 Free PMC article. No abstract available.
67 results